The effects of multi-nutrient formulas containing a combination of n-3 PUFA and B vitamins on cognition in the older adult: a systematic review and meta-analysis.

This systematic review and meta-analysis investigated whether supplementing with a combination of n-3 PUFA (n-3 polyunsaturated fatty acids, like EPA and DHA found in fish oil) and B vitamins (specifically B12, B6, and folic acid) could prevent cognitive decline in older adults.

The interventions studied were:

**Combined n-3 PUFA and B vitamins:** These were provided either alone or, more commonly, as part of a broader multi-nutrient formula that included other beneficial compounds.

**Single nutrient interventions:** Some included trials provided n-3 PUFA alone while also measuring B vitamin status, or provided B vitamins alone while measuring n-3 PUFA status, to explore potential interactions.

The comparators were **placebo supplementation**.

The outcome measures focused on various aspects of cognitive function, assessed using neuropsychological tests:

**Global cognition:** This refers to overall mental ability. It was assessed in two ways:

* **Composite scores:** Derived from a battery of multiple neuropsychological tests, providing a comprehensive measure of overall cognitive status. This was considered the primary outcome.

* **Single measures:** Individual tests designed to assess global cognitive function.

**Episodic memory:** The ability to recall specific events, experiences, and information from the past.

**Executive function:** Higher-level cognitive skills involved in planning, problem-solving, decision-making, and self-control.

The meta-analysis synthesized data from 14 individual randomized controlled trials (RCTs), involving a total of **4913 participants**.

The population studied consisted of **older adults**, with a mean age generally ranging from **60 to 70 years**. The specific cognitive health status of participants at baseline varied across the included studies, with some participants being healthy older adults and others experiencing mild cognitive impairment (MCI). The review aimed to include studies where the mean age of participants was 60 years or greater.

The studies were conducted in various settings globally, as is typical for a systematic review drawing from diverse published research.

The individual studies included in the meta-analysis measured cognitive function using various **neuropsychological tests**. These tests are standardized assessments designed to evaluate different cognitive domains.

For the purpose of this meta-analysis, the researchers categorized these measurements:

**Composite scores from a neuropsychological test battery:** This involved combining results from several different cognitive tests into a single, overall score for global cognition. This approach is considered more sensitive for detecting subtle cognitive changes, especially in healthy older adults or those with mild cognitive impairment, compared to single, broad screening tests like the Mini-Mental State Examination (MMSE).

**Single measures of cognition:** These were individual tests that assessed specific aspects of global cognition, episodic memory, or executive function. Examples of such tests, though not explicitly detailed in the abstract, would typically include tasks like word recall lists, digit span tests, or various executive function tasks (e.g., Stroop test, Trail Making Test).

To combine results from different cognitive tests, which often use different scoring scales, the researchers calculated a **Hedges G statistic** for each effect size. Hedges G is a standardized mean difference, similar to Cohen's d, but it includes a correction for bias that can occur with small sample sizes. This allowed them to compare and combine findings across studies despite variations in the specific tests used. For consistency, all cognitive test scales were adjusted so that a positive Hedges G value indicated a benefit from the intervention group, and a negative value indicated a benefit from the placebo group.

The meta-analysis also extracted data on relevant biomarkers where available, such as n-3 PUFA levels, B vitamin levels, or homocysteine levels, to assess the nutritional status of participants and explore potential interactions between nutrients.

This study was a **systematic review and meta-analysis** of **randomized controlled trials (RCTs)**. This is considered the highest level of evidence for determining the effectiveness of interventions.

**Study Design and Search Strategy:**

The review was pre-registered with PROSPERO (CRD42020210361), a public registry for systematic reviews, which enhances transparency and reduces the risk of reporting bias.

The research question was structured using the PICO (Population, Intervention, Control, Outcome) framework.

Researchers systematically searched five major scientific databases (The Cochrane Library, EMBASE, CINAHL, Scopus, and MEDLINE) in December 2020 for articles published between January 2010 and December 2020.

The search terms included keywords related to n-3 PUFA (e.g., eicosapentaenoic acid, EPA, docosahexaenoic acid, DHA, fish oil) and B vitamins (e.g., B12, folic acid, folate, homocysteine, multivitamin). These terms were combined using Boolean operators (AND/OR) to capture relevant studies. Supplementary searches were also conducted by examining reference lists of relevant articles.

**Inclusion and Exclusion Criteria for Individual Studies:**

**Included:**

* Randomized controlled trials (RCTs) published in English. The decision to limit to RCTs is crucial because RCTs are designed to minimize bias and allow for causal inferences. They provide a controlled and consistent dosage of nutrients.

* Participants with a mean age of 60 years or greater.

* Interventions providing a combination of n-3 PUFA and B vitamins, either alone or as part of a multi-nutrient formula.

* Studies that tested for interactions between n-3 PUFA and B vitamins by providing one nutrient alone but objectively measuring the status of the other (e.g., n-3 PUFA supplementation with B vitamin status measurement, or vice versa).

* Studies that assessed cognitive function through changes in a composite score from neuropsychological testing or changes in single cognitive test scores.

**Excluded:**

* Duplicated publications.

* Non-randomized control trials (e.g., observational studies, case reports, reviews, in vitro, animal studies). This exclusion strengthens the causal claims but might limit the breadth of evidence.

* Studies that did not report specific dosages for individual nutrients provided in supplements, ensuring that the interventions were clearly defined.

**Data Extraction and Risk of Bias Assessment:**

Data extraction was performed by one reviewer and checked for accuracy by a second reviewer for 30% of the extracted data.

The risk of bias for each included RCT was independently assessed by two reviewers using the **Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)**. This tool evaluates five domains:

1. Bias arising from the randomisation process (e.g., was allocation truly random and concealed?).

2. Bias due to deviations from the intended interventions (e.g., was blinding maintained? Were participants adhering to the intervention?).

3. Bias due to missing outcome data (e.g., were dropouts handled appropriately?).

4. Bias in the measurement of the outcome (e.g., were outcome assessors blinded?).

5. Bias in the selection of the reported result (e.g., was the primary outcome pre-specified?).

Disagreements were resolved through discussion or by consulting a third independent researcher, ensuring a robust assessment of study quality.

**Statistical Approach (Meta-analysis):**

**Effect Size Calculation:** For each study, the Hedges G statistic was calculated based on the mean differences (post-study minus pre-study scores) and standard deviations between the intervention and placebo groups. This standardized effect size allowed for the combination of results from studies using different cognitive tests and scales.

**Meta-analysis Model:** A **random-effects meta-analysis model** was used to generate overall effect sizes. This model assumes that the true effect size varies across studies (due to differences in populations, interventions, etc.) and accounts for both within-study and between-study variability. This is generally more appropriate than a fixed-effect model when there is expected heterogeneity among studies.

**Heterogeneity Assessment:** Statistical heterogeneity (the variability in results across studies) was assessed using the **χ² test** and the **I² statistic**.

* P > 0.1 for the χ² test and I² < 50% indicated low heterogeneity.

* I² > 50% indicated high heterogeneity, suggesting that the observed effects might not be consistent across all studies.

**Primary and Secondary Analyses:**

* **Primary analysis:** Focused on studies that used a **composite score from a neuropsychological test battery** to assess global cognitive status. This was prioritized because composite scores are considered more sensitive for detecting early cognitive changes.

* **Secondary analyses:** Performed on single tests of global cognition, episodic memory, and executive function.

**Subgroup Analysis:** A subgroup analysis was planned based on participants' cognitive health status at baseline (e.g., healthy older adults vs. those with mild cognitive impairment) to see if the effects differed in these groups.

**What this design can and cannot prove:**

**What it *can* prove:**

* **Causal inference:** By synthesizing data from multiple RCTs, this meta-analysis provides strong evidence for a causal relationship between the combined n-3 PUFA and B vitamin supplementation (especially as part of multi-nutrient formulas) and improvements in specific cognitive domains in older adults. RCTs, by their nature, are designed to establish cause and effect.

* **Generalizability:** By pooling data from various studies, a meta-analysis can provide a more precise and generalizable estimate of the effect than any single study, increasing confidence in the findings.

* **Identification of interactions:** The inclusion criteria allowed for studies exploring interactions between n-3 PUFA and B vitamins, which is a key strength in understanding potential synergistic effects.

**What it *cannot* prove:**

* **Individual study quality:** While the RoB 2 tool assesses the risk of bias in individual studies, a meta-analysis cannot improve the quality of poorly designed or executed original studies. If many included studies have a high risk of bias, the overall conclusion may still be affected.

* **Specific nutrient contribution:** When the intervention is a "multi-nutrient formula" containing n-3 PUFA and B vitamins *alongside other nutrients*, it becomes difficult to isolate the precise contribution of *only* n-3 PUFA and B vitamins versus the other components. The abstract notes this, stating the benefit was from "nutrient formulas, which included both n-3 PUFA and B vitamins alongside other nutrients."

* **Long-term effects beyond study duration:** The follow-up duration of included studies ranged from 24 weeks to 4 years. While this is substantial, it doesn't necessarily predict effects over a lifetime or in very advanced stages of cognitive decline.

* **Applicability to younger populations:** The study specifically focused on older adults (aged 60+), so its findings cannot be directly extrapolated to younger individuals.

**Major Methodological Strengths:**

Systematic review and meta-analysis of RCTs, providing high-level evidence.

Pre-registered protocol (PROSPERO) for transparency.

Comprehensive search strategy across multiple databases.